Heart Foundation applauds new vaping reforms to curb e-cigarette use in Australia

The Heart Foundation has welcomed the Australian Government’s commitment to new vaping reforms designed to curb e-cigarette use in Australia.

From January 1, 2024, the Government will implement a ban on the importation of disposable single use vapes, while improving access to therapeutic, medically prescribed vapes, for people trying to quit smoking.

From March 1, 2024, further changes are expected to commence, including the:

  • A cessation of the personal importation of vapes.
  • A ban on the importation of non-therapeutic vapes.
  • A requirement for therapeutic vape importers and manufacturers to notify the Therapeutic Goods Administration of their product’s compliance with the relevant product standards.
  • Requirement for importers to obtain a licence and permit from the Australian Government’s Office of Drug Control before the products are imported.

We welcome any Government intervention when it comes to curbing vaping use, especially among the young. Vaping, or the use of electronic cigarettes (e-cigarettes), has gained popularity in recent years as an alternative to traditional tobacco smoking.

The use of e-cigarettes containing nicotine can lead to an increase in heart rate and blood pressure, which may pose longer term risks to users’ cardiovascular health and increase the risk of future heart events.

Meanwhile, young Australians who vape are roughly three times more inclined to start tobacco smoking, when compared to other young people who have never vaped.

Smoking has significant adverse effects on heart health, and it is a major risk factor for cardiovascular diseases. Secondhand smoke exposure is also harmful to heart health. Non-smokers exposed to secondhand smoke have an increased risk of developing heart disease.”

David Lloyd, Chief Executive Officer, Heart Foundation 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
CRISPR-based therapy shown to be safe, effective for people with transthyretin amyloidosis